BUY Dr. Lal Path Labs Ltd. — Citigroup
byCitigroupHorizon: NA (inferred 1 year)9 Jul 2026via NDTV Profit (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·30 Jul · 4d ago
Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?
NewsEt-Markets·27 Jul · 1w ago
1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·27 Jul · 1w ago
Dr. Lal PathLabs reported Q1 FY27 results with revenue up 19.1% to Rs 798 Cr. EBITDA increased 28.7% to Rs 247 Cr. PAT was Rs 170 Cr. The company also announced an interim dividend of 50% (Rs 5/share)
BSE · Company Update·24 Jul · 1w ago
Dr. Lal Path Labs Ltd. announced its Q1 FY27 financial results, reporting a revenue of Rs 798 Cr, a 19.1% increase year-on-year. EBITDA grew by 28.7% to Rs 247 Cr, and PAT increased by 27.2% to Rs 170
NSE · Press Release·24 Jul · 1w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.